All In Biotech

Drug Trial Radar · NCT00620854

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Feb 2008

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Tarsa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
Female only, from 45 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).

Conditions

  • Osteoporosis

Interventions

  • Recombinant Salmon Calcitonin (rsCT)Drug

    Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.

  • Oral TabletDrug

    0.15 mgs recombinant salmon calcitonin, single oral dose

  • Oral TabletDrug

    0.2mgs recombinant salmon calcitonin, single oral tablet

  • Nasal SprayDrug

    200 IU recombinant salmon calcitonin, single intranasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma C-terminal Telopeptide of Type I Collagen (CTx-1)(% Change From Baseline)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours (Fortical): 0, 2, 3, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 10, 12, 24 hours rsCTA and rsCTB

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bio-Kinetic Clinical Applications, Inc.

    Springfield, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.